Molecular Imaging and Theranostics in Prostate Cancer – the Future Begins Today
The EANM is very pleased to announce the fifth Focus Meeting on the topic of prostate cancer.
The aim of this meeting is to critically assess the latest developments in molecular hybrid imaging and systemic radionuclide therapy in prostate cancer, to reach a multidisciplinary consensus on the current state-of-the-art and to generate expert recommendations on how to guide the field towards establishing clinical impact.
- Early Registration Fee (until October 31, 2022) – EUR 650.00
- Late Registration Fee (from November 1, 2022) – EUR 850.00
As in the past years, EANM will seek accreditation from the European Accreditation Council for Continuing Medical Education (EACCME).